TH3933A - Broad-spectrum vaccines used against gonorrhea? - Google Patents

Abstract

The disclosure of the vaccine's manufacturing process, which involves the arrangement of peptides related to the immunorecessive determinant in the gonorrhea pilus protein, reveals that the vaccine would provide human immunity against various types of gonorrhea by stimulating antibodies to interfere with the colonization of the cell wall caused by the bacteria or by inducing phagocytosis.

Claims (13)

1. The process used to prepare a vaccine that provides immunity against gonorrhea. People, which consists of quantities that produce an immune-boosting effect. peptides Containing an amino acid sequence at positions 21-35. 41-50 48-60, 69-84, 107-121, 135-151, or 151-159, which is the movement. It consists of conjugating any of the aforementioned peptides to a support. at It is mostly an antigenic neutral. 2. The process used to prepare the vaccine that provides immunity against gonorrhea. In humans, it contains the amount that produces an immune-boosting effect. Peptides are peptides that have a predominantly amino acid arrangement and... It would be similar to the amino acid arrangement of N. gonorrhea MS. 11 (Tr) Philin at positions 21-35, 41-50, 48-60, 69-84, 107-121 135-151 or 151-159, where the process involves cultivation. Animal or plant cells that, when recombined, can produce peptides. The aforementioned peptide provides, or connects, the amino acids of the peptide. In order, 3. The process as claimed in claim 1, which involves a matching peptide. They are positioned at 21-35, 41-50, 48-60, 69-84, or 151-159. The cys at the N- end is truncated, including the cys at the C- end. 4. The process as claimed in claim 1, which involves a matching peptide. They are positioned at 21-35, 41-50, 48-60, 69-84, or 151-159. The Cys molecule is cleaved by multiple N-nodes, including the Gly-Cys dipeptide at its end. C- as well. 5. The process as claimed in claim 1 or 2, which involves peptides. The above can be selected from a group consisting of: (a) Glu-Gly-Gln-Lys-Ser-Ala-Val-Glu-Tyr; (b) Pro-Pro-Ser-Asp-Ile-Lys-Gly-Lys-Tur-Val-Lys-Glu-Val-Gl u-Val-Lys; (c) Leu-Pro-Ala-Tyr-Gln-Asp-Tyr-Thr-Ala-Arg-Ala-Gln-Val-Se r-Glu; (d) Thr-Glu-Tyr-Tyr-Leu-Asn-His-Gly-Lys-Trp-Pro-Glu-Asn; (e) Ser-Leu-Trp-Ala-Arg-Arg-Glu-Asn-Gly-Ser-Val-Lys-Trp-Ph e-Cys; (f) Asp-Ala-Lys-Asp-Gly-Lys-Glu-Ile-Asp-Thr-Lys-His-Leu-Pr o-Ser-Thr-Cys; and (g) Cys-Arg-Asp-Lys-Ala-Ser-Asp-Ala-Lys 6. The process as claimed in claim 5, which involves the arrangement of... The amino acids a-d or g with Cys at the N- end are truncated. This includes Cys at the C- end or Gly-Cys at the C- end. 7. The process as claimed in claim 5, which involves the aforementioned peptide. It is said that there is an arrangement of type (a). 8. The process as claimed in claim 5, which includes the aforementioned peptide. It is said that there is a type (b) arrangement. 9. The process as claimed in claim 5, which includes the aforementioned peptide. It is said that there is a (c) arrangement. 10. The process as claimed in claim 5, which includes the aforementioned peptide. It is said that there is a type (d) arrangement. 11. The process as claimed in claim 5, which includes the aforementioned peptide. It is said that there is an arrangement of type (e). 12. The process as claimed in claim 5, which includes the aforementioned peptide. It is said that there is an arrangement of type (f). 13. The process as claimed in claim 5, which includes the aforementioned peptide. It is said that there is a (g) arrangement. (13 claims, 4 pages, 1 image)